HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, & Surveillance Pipeline
Authors:
- Stephen KanyereziSKStephen Kanyerezi
- Ivan SserwaddaISIvan Sserwadda
- Aloysius SsemagandaASAloysius Ssemaganda
- Alisen AyitewalaAAAlisen Ayitewala
- Hellen Rosette OundoHOHellen Rosette Oundo
- Brian A. KagurusiBKBrian A. Kagurusi
- Godwin TusabeGTGodwin Tusabe
- Isaac SsewanyanaISIsaac Ssewanyana
- Susan NabaddaSNSusan Nabadda
Preprint
- 21 June 2024
- preprint
- Published by Microbiology Society
- p. 000815.v2
Abstract
The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently, integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated while ensuring data security and privacy of patient information. To address these challenges, here, we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short-reads, FASTA, and Sanger ab1.seq files.Keywords
All Related Versions
- Published version: Access Microbiology, 6 (7), 000815.v3.
Funding Information
- Eastern Africa Network of Bioinformatics Training (EANBiT) project
- African Doctoral Dissertation Research Fellowship (ADDRF)
- EDCTP (TMA2020CDF-3159)
- Foundation for the National Institutes of Health (U2RTW010672)
- Foundation for the National Institutes of Health (U2RTW012116)
- CAGE-TB Project
- PHA4GE (INV-038071)